Pfizer's palbociclib has fans, but will share the field

Share this article:
Pfizer's palbociclib has fans, but will share the field
Pfizer's palbociclib has fans, but will share the field

Pfizer's experimental CDK-4/6 inhibitor palbociclib has a lot riding on it. ISI Group analyst Mark Schoenebaum has previously noted that it is the molecule on which one of the two theoretical free-standing innovative Pfizer companies depends, and Sanford Bernstein analyst Tim Anderson writes in his Thursday research note that Phase II and Phase III trials have made it one of the company's “most closely watched late-stage pipeline products.”

Leerink Swann analyst Seamus Fernandez projected in April that palbociclib could rake in $3 billion with only a first-line metastatic cancer indication. Anderson expects $1.9 billion in sales by 2020. Pfizer said Thursday that it teamed up with GlaxoSmithKline in a palbociclib-trametinib pairing for melanoma.

Yet, Anderson is intrigued by what's not being talked about: Novartis is silently stalking Pfizer's potential first-in-class, small-molecule CDK-4/6 inhibitor with its own candidate, the Phase III LEE011. Like Pfizer, Novartis is testing the drug in breast cancer against letrozole. Anderson said the company looks to be in Phase I/II tests in lymphoma and pediatric tumors.

A win could wipe away the sting from Novartis's recent layoffs and provide some cover as competitors start to challenge Gilenya (MS) and Lucentis (wet AMD).  

Anderson also noted that Eli Lilly could also keep palbociclib from taking over the market. He puts Lilly's LY2835219 in third place among the possible contenders, but notes that the Indiana drugmaker is claiming its entrant in the race is a “cleaner version” of Pfizer's CDK-4/6 inhibitor.

Anderson wrote that he hasn't crunched numbers for expected Lilly or Novartis sales if their drug candidates were to make it to market.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...